Flow Cytometry Market Size, Share & Industry Analysis, By Product & Service (Instrument, Reagents & Consumables, and Software & Services), By Technology (Cell Based and Bead Based), By Application (Clinical and Research), By End-user (Pharmaceutical & Biotechnology Industries, Academic & Research Organizations, Hospital & Diagnostic, and Others), and Regional Forecast, 2024-2032

The global flow cytometry market size was valued at USD 5.70 billion in 2023. The market is projected to grow from USD 6.16 billion in 2024 to USD 11.90 billion by 2032, exhibiting a CAGR of 8.6% during the forecast period. North America dominated the global market with a share of 39.65% in 2023.

Flow cytometry is an analytical tool used to measure and analyze several physical characteristics of cells or particles suspended in a fluid using a laser beam. The method helps to sub-classify cell types and detect residual levels of disease. It is also used for cell counting and evaluation of allograft recipients, both before and after organ transplantation. There are two types of technology available in the market such as cell-based and bead based technology. Companies in the market are constantly focusing on innovation and up-gradation of their product portfolio with new and efficient product offerings.

The flow cytometry market growth is attributed to the increasing incidence and prevalence of chronic diseases across the world. Growing initiatives in the field of immunology and immuno-oncology research and increasing adoption of advanced techniques in research are expected to boost the growth of the market. Furthermore, the adoption of recombinant DNA technology for antibody production and evolving pipeline for stem cell research is likely to offer significant growth opportunities for market players.

Furthermore, a positive impact on the market was observed during the COVID-19 pandemic. The demand for flow cytometers and their services increased during the 2020 pandemic as these devices were utilized to diagnose the clinical progression of the virus. This led to the increasing adoption of instruments and reagents during the pandemic. Additionally, the market players witnessed the growth in the sales of the flow cytometry products. From 2022 onwards, the market is projected to grow at a steady CAGR during the forecast period.

Flow Cytometry Market Trends

Increasing Focus on Development of Next-generation Flow Cytometry to Augment Market Growth

In recent years, next-generation flow cytometry has emerged as a solution to overcome the limitations of conventional technology and as a complement to genetic and imaging methodologies.

With the development of these cytometers, the instrument can stain cells with 20-30 colors at once, which increases the number of leukemia-associated immunophenotypes which can be tracked. Such availability of advancement in these next-generation technologies is expected to propel the growth of the market during the forecast period.

In addition, market players are focusing on development to continuously provide cutting-edge technologies to drug developers and patients and industry-leading laboratory testing solutions.

• For instance, in May 2019, Q2 Solutions collaborated with Cytek Biosciences and adopted the next-generation of flow cytometry systems in eight laboratories including North America, China, Asia Pacific, and Europe.


• In addition, in June 2023, BD launched the FACSDuet system, an automated instrument to prepare samples with the help of robotics for clinical diagnostics using flow cytometry to improve standardization and reproducibility in cellular diagnostics.

Request a Free sample to learn more about this report.

Flow Cytometry Market Growth Factors

Increasing Awareness of Chronic Diseases to Boost Product Demand

In recent years, there has been an increase in the prevalence of these chronic diseases such as leukemia, HIV/AIDS, and cancer. This has increased the demand for awareness of advanced technologies, such as flow cytometer, to diagnose and conduct research related to chronic diseases.

• For instance, according to the Leukemia & Lymphoma Society, in 2023, around 437,337 individuals in the U.S. were living with leukemia, and 59,610 cases were diagnosed with it.

With the growing awareness of these systems, such as instruments, reagents, software, and services, the market players have increased their focus on developing and introducing new and advanced systems which will help diagnose chronic diseases. 

• For instance, in August 2019, Sysmex Corporation launched the PS-10 flow cytometry sample preparation system in North America for pharmaceutical companies and universities to research cancer and regenerative medicine.

The rising focus of market players to launch advanced flow cytometer sample systems and instruments for research and clinical application for the growing prevalence of chronic diseases is expected to drive market growth in the coming years.

Technological Advancements to Drive the Market Growth

The increased focus of market players in developing and introducing novel and technologically advanced products is one of the major factors propelling the use of the flow cytometer software, and reagents in various clinical and research applications.

Various European organizations initiated many efforts such as standardizing diagnosis to facilitate clinical feasibility and reproducibility and standardization of antibody panels and laboratory procedures. Such standardization of laboratory protocols is expected to boost the adoption of these products & services in clinical applications and stimulate the market players to introduce solutions for diagnosis.

• For instance, in February 2020, Beckman Coulter Life Sciences rolled out DxFLEX. It was the first CE-IVD, 13-color clinical system in Europe. The resolution and sensitivity of flow cytometer increase laboratory testing capabilities.


• In May 2023, Sysmex Corporation launched the Flow Cytometer XF-1600. The product is a clinical flow cytometry. This system automates the entire clinical flow cytometry testing process for the diagnosis and analysis of hematological diseases such as leukemia and malignant lymphoma. This automation, when combined with monoclonal antibody reagents, enhances the efficiency and standardizes the testing procedures. Such technological advancements are expected to play a major role in the global flow cytometry market growth during the forecast period.

Such technological advancements are expected to play a major role in the market's growth during the forecast period.

RESTRAINING FACTORS

High Cost and Limitations Associated with the Instruments to Hamper Market Growth

Despite the wide clinical and research applications of flow cytometer, high cost and lack of awareness of technical expertise are projected to hamper the global market growth in the upcoming years.

Flow cytometers are expensive and many emerging economies cannot afford technologically advanced flow cytometers. The flow cytometers are advanced instruments but are more expensive than alternatives such as radioimmunoassay and enzyme-linked immunosorbent assay. These instruments cost between USD 75,000 and USD 100,000 for a four- to six-color and two-laser instrument, posing a financial burden on small and medium-sized hospitals and diagnostic laboratories in emerging economies.

Furthermore, there are several complications associated with flow cytometers, such as mechanical complexity, bulky size, and the need for highly trained personnel which have limited the utility of the instruments, thereby hampering the market expansion over the estimated period.

The limitations associated with flow cytometers technology and high cost are the factors that can restrict the market during the forecast timeframe.

Flow Cytometry Market Segmentation Analysis

By Product & Service Analysis

Instruments Segment to Dominate Driven by Surging Adoption of Cell Sorters

On the basis of product & service, the market is categorized into instruments, consumables & reagents, and software & services.

The instruments segment is further divided into analyzer and cell sorter. The instrument segment accounted for the largest portion of the global flow cytometry market share in 2023 and is set to grow at a moderate CAGR during the estimated period. The dominant share of this segment can be attributed to numerous aspects such as technological advancements in analyzers and cell sorting instruments and the increasing focus of healthcare providers toward the usage of capital equipment devices.

• For instance, in February 2024, the Interuniversity Microelectronics Centre (IMEC) collaborated with the KU Leuven Laboratory of tumor immunology and Immunotherapy to validate the cell sorter chip technology. This technology successfully identified the PD-1 positive T cells in ovarian cancer patients. Such advances in the segment lead to the growth of the market.

Moreover, the growing focus of market players to launch advanced instruments is estimated to support the segment in the maintenance of its dominant share over the estimated period.

To know how our report can help streamline your business, Speak to Analyst

By Technology Analysis

Bead Based Segment to Grow at Highest Growth Rate Due to Rapid Introduction of Advanced Products

Based on technology, the market is fragmented into cell based and bead based.

In 2023, the cell based segment held the highest market share and was anticipated to expand at a substantial CAGR during the forecast period (2024-2032). The growth is attributable to various factors such as the increased prevalence of chronic diseases, including cancer and HIV-AIDS, and increasing patient visits to the hospital and clinics for the diagnosis of these diseases. Furthermore, increasing launches of consumables and reagents for cell based instruments are expected to propel the segment in the forecast timeframe.

The bead based segment is projected to expand at the highest CAGR during the study period. The advantages associated with bead based technology include high sensitivity enabling the detection of low amounts of (mutated) DNA. Beads are more stable than cells and can withstand harsh experimental conditions, thus reducing the variability. Furthermore, it allows the reproducible detection of the extracellular vesicles, and the cost-effectiveness of the beads leads to more cost-efficient options for large-scale studies. Further, it allows reproducible detection of extracellular vesicles. These benefits are expected to propel the segment growth in the long run.

By Application Analysis

Research to Hold a Major Share Due to Increasing Investments in the Healthcare Research Industry

Based on application, the market is segmented into clinical and research.

The research segment accounted for the highest market share in 2023 and is set to grow at a considerable CAGR over the estimated period. The growing research & development investments in the biopharmaceutical, life science, and biotechnology research industry is propelling the demand for these products and services, which is expected to boost segmental growth during the forecast period.

• For instance, in February 2024, the Cancer Prevention and Research Institute of Texas (CPRIT) awarded an estimated USD 100.0 million in grants to foster the state’s research initiatives for cancers. The committee approved an estimated USD 73.0 million for 46 academic research grants. Such developments are expected to contribute to segmental growth during the forecast period.

The clinical segment is anticipated to expand at the highest CAGR during the forecast period, 2024-2032. The high growth rate is attributed to the rising technological advancements and product launches of analytical tools, such as the development of microfluidic flow cytometry for point-of-care testing. Furthermore, the growing prevalence of infectious diseases, especially in developing countries, is expected to boost the demand for the diagnosis of these diseases, thereby increasing segmental growth in the long run.

By End-user Analysis

Large Patient Volumes in Hospital & Diagnostics to Drive Segmental Expansion

In terms of end-user, the market is fragmented into pharmaceutical & biotechnology industries, academic & research organizations, hospital & diagnostics, and others.

The hospital & diagnostics segment is expected to grow at the highest CAGR during the forecast period. The growing population suffering from chronic diseases and a major group of the patient population visiting diagnostic centers and hospitals for conducting diagnosis contribute to the market growth. Moreover, the reliability of patients toward government hospitals in developing countries and the growing number of hospitals across the world are some of the major factors escalating the patient visits for diagnosis in these end-user settings.

REGIONAL INSIGHTS

Based on region, the market has been analyzed across North America, Europe, Asia Pacific, and the rest of the world.

To get more information on the regional analysis of this market, Request a Free sample

The North America market accounted for USD 2.26 billion in 2023 and is projected to expand at a moderate CAGR over the estimated period. The rise is due to the rapid introduction of software and services, the increasing adoption of clinical flow cytometers and their reagents, research for drug development, and the launch of advanced solutions by prominent companies.

Europe is anticipated to expand at a substantial CAGR over the analysis period. The rise is due to the increasing population of chronic diseases coupled with increasing demand for research to treat these diseases. Furthermore, the growing CE approvals and introduction of flow cytometers are expected to boost the market in Europe.

The market in Asia Pacific is anticipated to expand at the highest CAGR over the estimated period. The surge can be attributed to the rising awareness regarding chronic diseases and the escalating adoption of consumables and reagents. Furthermore, the rising focus of companies for the expansion of their geographical presence by rolling out new products is the key factor set to impel market expansion over the forecast period.

The market in the rest of the world, including Latin America and the Middle East & Africa is set to grow at a lower CAGR than other regions over the estimated period. The expansion is attributable to various factors such as the increasing prevalence of chronic diseases, such as HIV and cancer, and the escalating adoption of these devices.

List of Key Companies in Flow Cytometry Market

Introduction of Advanced Flow Cytometers by Companies to Strengthen their Market Position

The market is consolidated owing to large market shares held by major players.  

The key companies operating in the market are BD, Danaher, and Miltenyi Biotec. In 2023, these three companies together accounted for a major flow cytometry market share.

BD's research flow cytometer has been in the market for many years and has continued to perform well even with the introduction of new research products. The highest share can be credited to its robust product portfolio and growing focus on the launch of new advanced flow cytometers and consumables in the market.

• In April 2022, BD (Becton Dickinson and Company) introduced BD Horizon RealYellow 586 Reagents, the first fluorochrome in the new BD Horizon RealYellow and RealBlue Reagents product family. These products are an advancement in the market and can potentially accelerate disease discovery and drug development.

Other companies with new product launches include DiaSorin S.p.A., Thermo Fisher Scientific, Bio Rad Laboratories, Inc., and other industry players. These market participants are focused on the launch of new instruments and reagents and the expansion of their geographical footprints.

LIST OF KEY COMPANIES PROFILED:

• Miltenyi Biotec (U.S.)


• BD (U.S.)


• Bio-Rad Laboratories, Inc. (U.S.)


• Danaher (U.S.)


• Thermo Fisher Scientific (U.S.)


• Agilent Technologies, Inc. (U.K.)


• DiaSorin S.p.A. (Italy)


• Sysmex (Japan)


• Apogee Flow Systems Ltd. (U.K.)


• Sony Biotechnology Inc (U.S.)

KEY INDUSTRY DEVELOPMENTS:

• January 2024- Biotium launched Biotium choice monoclonal primary antibody conjugates with the aim of delivering outstanding performance for flow cytometry.


• May 2023- BD launched FACSDiscover S8 Cell Sorter, a new cell sorting instrument with two technologies: CellView Image Technology and SpectralFX Technology. This enables researchers to explore deeper details of cells that were previously unseen in standard flow cytometry experiments.


• May 2023- BD collaborated with Sehgal Path Lab to launch the Centre of Excellence (CoE) in Flow Cytometry in Mumbai for clinical research.


• April 2022 - Bio-Rad Laboratories, Inc. introduced three StarBright Dyes designed for use with a 355 nanometer UV laser in flow cytometer applications.


• June 2020 - Apogee Flow Systems Ltd. formed a new subsidiary, Apogee Flow Asia Ltd., in Hong Kong, Asia, to expand its customer base.


• April 2020 - Merck rolled out its new benchtop flow cytometer system dubbed CellStream. Equipped with a camera, the solution is a customizable and compact flow cytometer.


• January 2019 - Miltenyi Biotec demonstrated the MACSQuant X Fully-Automated System at Society for Laboratory Automation and Screening (SLAS) – 2019 to increase its customer base.


• January 2019 - DiaSorin S.p.A.'s Luminex Corporation shared plans to acquire MilliporeSigma's flow cytometer portfolio. The deal involved a transaction value of USD 75.0 million.

REPORT COVERAGE

An Infographic Representation of Flow Cytometry Market

View Full Infographic

To get information on various segments, share your queries with us

The research report provides a detailed competitive landscape giving information related to key industry developments and new product launches. In addition, it covers the market dynamics such as market drivers, restraints, opportunities, and trends. Moreover, the report includes the prevalence of chronic diseases in key countries and the impact of COVID-19 on the market. Besides these, the report offers an overview of the technological advancement of flow cytometer and its consumables.

To gain extensive insights into the market, Request for Customization

Report Scope & Segmentation